

**APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052**

**Purchase of own shares - 7<sup>th</sup> Interim notification**

**Monheim am Rhein, 8 August 2022.** In the period from 1 August 2022 up to and including 5 August 2022, a total of 3,501 shares were purchased under the Share Buyback Program 2022/II. The launch and the details of the Share Buyback Program 2022/II were published by way of an announcement dated 23 June 2022 pursuant to Article 5 paragraph 1 of Regulation (EU) No. 596/2014 and Article 2 paragraph 1 of the Delegated Regulation (EU) No. 2016/1052.

The total number of shares purchased in the period from 1 August 2022 up to and including 5 August 2022 per day, exchange, average price and volume in euros are as follows:

Date	Total number of shares purchased (number)	Average price (Euro)	Exchange	Volume (Euro) <sup>1</sup>
02/08/2022	1,217	11.5039	Xetra	14,000.30
03/08/2022	301	11.4470	Xetra	3,445.55
04/08/2022	1,149	12.1544	Xetra	13,965.40
05/08/2022	834	12.0400	Xetra	10,041.40

1) Excluding acquisition costs

The total number of shares purchased to date as part of the Share Buyback Program 2022/II up to and including 5 August 2022 amounts to 41,848 shares.

The share buyback was carried out by Hauck Aufhäuser Lampe Privatbank AG.

Further details on the Share Buyback Program 2022 and the above transactions are published under the Corporate Governance section of the Company's Investor Relations website in accordance with Article 5 of Regulation (EU) No. 596/2014 and



pursuant to Delegated Regulation (EU) No. 2016/1052 (<https://ir.apontis-pharma.de/websites/apontispharma/English/4000/corporate-governance.html>).

**APONTIS PHARMA AG**

Investor Relations  
ir@apontis-pharma.de  
T: +49 2173 89 55 4900  
F: +49 2173 89 55 1521  
Alfred-Nobel-Str. 10  
40789 Monheim am Rhein  
Germany  
apontis-pharma.de

**APONTIS PHARMA Presse Contact**

CROSS ALLIANCE communication GmbH  
Sven Pauly  
ir@apontis-pharma.de  
T: +49 89 125 09 0330